Leukemia, Myeloid, Acute: all 3,035 studies

Page 4 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.

• Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.RecruitingNCT06812104Phase 1
• Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized StudyRecruitingNCT06811233Phase 2
• HVA vs IA/DA or VA in the Treatment of ND HR-AMLRecruitingNCT06810791Phase 3
• A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk LeukemiaRecruitingNCT06810583Phase 1
• Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid LeukemiaRecruitingNCT06802718Phase 3
• Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)RecruitingNCT06802315Phase 2
• Epidemiology of Infection in Acute Myeloid Leukemia (AML)Not yet recruitingNCT06797648
• L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AMLRecruitingNCT06788756Phase 2/3
• A Rollover Study for Continued Study Treatment and Ongoing Safety MonitoringEnrolling by invitationNCT06788509Phase 1
• Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AMLRecruitingNCT06786533Phase 1
• Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.Not yet recruitingNCT06786299Early Phase 1
• Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP InhibitorsRecruitingNCT06785077Not applicable
• Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCTRecruitingNCT06783790Phase 2
• NK Cell Infusion for Remission Consolidation in AML: A Phase II TrialNot yet recruitingNCT06783478Phase 2
• Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDXRecruitingNCT06782971
• Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction ChemotherapyRecruitingNCT06782542Phase 2
• Oral-ATO for TP53-mutated Myeloid MalignanciesRecruitingNCT06778187Phase 2
• A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)RecruitingNCT06773208Phase 2
• Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid LeukemiaRecruitingNCT06769490Phase 1
• Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic TreatmentsRecruitingNCT06764459
• A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06763341Phase 1
• A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06762132Early Phase 1
• Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06760260Early Phase 1
• Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.Not yet recruitingNCT06754540Phase 2
• BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid LeukemiaRecruitingNCT06746519Phase 1/2
• Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AMLRecruitingNCT06741722Phase 2
• Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AMLRecruitingNCT06737523Phase 1
• Relation of C-reactive Protein/ Albumin Ratio and Coagulation Profile in Acute Myeloid Leukemia PatientsNot yet recruitingNCT06714071
• IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.RecruitingNCT06713837Phase 3
• Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/LeukemiaRecruitingNCT06710418Not applicable
• Ivosidenib as Post-HSCT Maintenance for AMLRecruitingNCT06707493Phase 2
• Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous LeukemiaNot yet recruitingNCT06702098Early Phase 1
• A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their CaregiversRecruitingNCT06697600Not applicable
• Daunorubicin + Cytarabine + Venetoclax in de Novo AMLEnrolling by invitationNCT06697327Not applicable
• CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid LeukemiaRecruitingNCT06696846Phase 1
• Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive TreatmentRecruitingNCT06696183Phase 2
• Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCNRecruitingNCT06690827Phase 1
• Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDSRecruitingNCT06680752Phase 1/2
• Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)RecruitingNCT06672146Phase 2
• Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid LeukemiaNot yet recruitingNCT06667973Phase 2
• BCL2i CLAG-M in R/R Acute Myeloid LeukemiaRecruitingNCT06660368Phase 2
• ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid MalignanciesRecruitingNCT06656494Phase 1
• Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid LeukemiaNot yet recruitingNCT06652685Phase 2
• Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AMLRecruitingNCT06652438Phase 3
• Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML PatientsRecruitingNCT06651866Phase 1
• Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19RecruitingNCT06649227Phase 1
• Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction TherapyRecruitingNCT06643962Not applicable
• Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid LeukemiaNot yet recruitingNCT06643195Not applicable
• EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid LeukemiaRecruitingNCT06642025Early Phase 1
• A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined With Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.RecruitingNCT06641648Phase 1
• Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AMLRecruitingNCT06635681Phase 2
• APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AMLRecruitingNCT06634394Phase 1
• Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic InterventionRecruitingNCT06626893Not applicable
• Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AMLRecruitingNCT06621212Phase 2
• A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)RecruitingNCT06616636Phase 1
• Study of Oral PCLX-001 in R/R Acute Myeloid LeukemiaRecruitingNCT06613217Phase 1
• Twice-per-weekSelinexor, 2 Days MelphalanNot yet recruitingNCT06613035Phase 3
• TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.Not yet recruitingNCT06602323Phase 2
• Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid LeukemiaRecruitingNCT06599762Phase 2
• TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaNot yet recruitingNCT06598969Phase 2
• VA as Maintenance Therapy Post Allo-HSCT in MDS and AMLNot yet recruitingNCT06598384Phase 2
• HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AMLRecruitingNCT06594445Phase 1
• Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AMLRecruitingNCT06580106
• Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell TransplantRecruitingNCT06575296Phase 1
• RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CRRecruitingNCT06571825Phase 4
• Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AMLRecruitingNCT06561152Phase 1/2
• Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute LeukemiaNot yet recruitingNCT06559644Early Phase 1
• De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding PatientsRecruitingNCT06557421Phase 2
• Safety of MT-401-OTS in Patients With Relapsed AML or MDSRecruitingNCT06552416Phase 1
• Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCTRecruitingNCT06551584Phase 1
• A Clinical Trial of TQB3455 Tablets in Patients With Hematological MalignanciesRecruitingNCT06550713Phase 1
• Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06549790Phase 1
• A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)RecruitingNCT06548230Phase 1/2
• Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell TransplantRecruitingNCT06543381Phase 1
• Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid LeukemiaRecruitingNCT06537843Phase 2
• VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDSRecruitingNCT06536959Phase 2
• Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AMLRecruitingNCT06536010Not applicable
• Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid LeukemiaRecruitingNCT06535113
• Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDSRecruitingNCT06533761Phase 1
• Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid LeukemiaRecruitingNCT06532552Phase 2
• Sorafenib Relapase Prophylaxis After HCT With PTBCy RegimenRecruitingNCT06532084Phase 2
• Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06532058Phase 2
• Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT06529731Phase 2
• Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)RecruitingNCT06513273
• Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRDRecruitingNCT06511882Phase 2
• Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide TherapyRecruitingNCT06510868
• Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AMLRecruitingNCT06504459Phase 2
• A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic SyndromeRecruitingNCT06501196Phase 1
• Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell TransplantRecruitingNCT06498973Phase 1
• Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromesRecruitingNCT06484062Phase 1
• Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.RecruitingNCT06483906Phase 2
• Novel Digital Application for Patients With Acute LeukemiaRecruitingNCT06472128Not applicable
• CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AMLNot yet recruitingNCT06470841Phase 2
• ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AMLNot yet recruitingNCT06463327Phase 1
• Master Framework For Relapse or Refractory Acute Myeloid LeukemiaRecruitingNCT06459024
• The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid LeukemiaRecruitingNCT06458257
• The Efficacy of Allo-HSCT in ND HR-CBF-AMLRecruitingNCT06458244
• Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AMLRecruitingNCT06452732
• Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AMLRecruitingNCT06451861Phase 2
• A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaRecruitingNCT06448013Phase 1

← Leukemia, Myeloid, Acute overview